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• The Opioid Epidemic has led to a precipitous rise in the number of
overdose deaths across the United States as well as locally in
Spokane. Increasingly, overdose events have involved synthetic
opioids such as fentanyl1.
• Harm reduction strategies are evidence-based interventions for
minimizing overdose deaths and chance of relapse2.
• There are a wide variety of harm reduction strategies available for
patients with opioid use disorder. Buprenorphine, methadone,
and naloxone are some of the most commonly used harm
reduction strategies in addiction medicine; clean needle
exchanges and fentanyl testing strips (FTS) are less common2.
• FTS allow patients to avoid overdose by increasing knowledge
regarding what contaminants may be present in street drugs1.
• This project therefore attempted to address several issues for our
opioid related disorder patients. First, expanding available harm
reduction modalities with FTS, and second, establishing a baseline
and refining future methods to track harm reduction efforts at the
clinic.

AIMS STATEMENT
All psychiatric residency clinic patients with an opioid related disorder
diagnosis will be at least 50% equipped with naloxone by April 1, 2022
as demonstrated by the presence of naloxone on their outpatient
medication lists.
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Figure 1: Comparison of relative effectiveness by method of data extraction tools for correctly
identifying patients who have been provided naloxone kits.
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• Data was initially planned to be extracted primarily from Slicer-Dicer
using automated reporting. However, an initial portion of the first
PDSA cycle revealed failure of Slicer-Dicer to reliably report accurately
whether patients had naloxone or Narcan on their medication lists.
Automated reporting was dramatically less reliable, finding less than
half of patients with naloxone on their medication lists (21% versus
68%, respectively, see figure 1).
• Standardized templates were introduced to Recovery Clinic follow-up
progress notes that included documentation via smart-lists on the
harm reduction engagement status of the patient.
• Residents were also asked to ensure patients who had already
received naloxone kits had it listed as one of their medications in that
encounter.
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METRICS: Outcome, process, and balancing
• Outcome: Percentage of patients with opioid related
disorder diagnoses who have an active naloxone
prescription (68%).
• Process: Percentage of patients with an active
prescription for naloxone or have a supply at home but
have not had this entered into their medication list (20%).
• Balancing: Percentage of patients that have opioid use
disorders in sustained remission and are neither
interested in naloxone nor medication assisted therapy
(11%).
DISCUSSION & NEXT STEPS
This project likely had a significant effect on the number of
patients equipped with harm reduction tools in our clinic
population. The initial estimate was 21% of patients having
naloxone on their medication lists, while the final review
totaled 68% (and potentially as high as 88%). The certainty
of this statement is somewhat obscured by the initial
statistics being reliant on Slicer-Dicer’s less effective data
extraction tools. Since the effect size is not easily
quantifiable, it is at least plausible that the apparent
increase in patients equipped with naloxone is in part due to
standardizing documentation of harm reduction
optimization in Recovery Clinic note templates and in
difference in sensitivity with manual review. Other obstacles
that are relevant when using naloxone’s presence on
medication lists to approximate whether patients have harm
reduction tools available is that they will often tell nurses
that they aren’t actively taking naloxone, which will lead to it
being “discontinued” as a medication. Next steps include
tracking individual components of harm reduction
mobilization, such as FTS distribution, and individual
provider feedback regarding resident patient panel’s relative
harm reduction optimization.
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